When compared to CD7-negative CD7-CAR-T cells, NS7CAR-T cells exhibited similar anti-tumor properties and have already passed phase 1 clinical trial recruiting patients with T-ALL or T-cell lymphoblastic lymphoma (NCT04572308) (196). This evidence concerns the gene CD7 and neoplasm.